Fluent, Inc. (FLNT)’s Chief Executive Officer Ryan Schulke Purchases $1.40 million of the Company; Endocyte Has 2.32 Sentiment

Sentiment for Endocyte Inc (ECYT)

Endocyte Inc (ECYT) investors sentiment increased to 2.32 in 2018 Q1. It’s up 0.96, from 1.36 in 2017Q4. The ratio is positive, as 51 investment managers started new or increased stock positions, while 22 reduced and sold equity positions in Endocyte Inc. The investment managers in our database reported: 41.55 million shares, up from 19.91 million shares in 2017Q4. Also, the number of investment managers holding Endocyte Inc in top ten stock positions increased from 0 to 2 for an increase of 2. Sold All: 10 Reduced: 12 Increased: 24 New Position: 27.

The stock increased 0.42% or $0.06 during the last trading session, reaching $14.28. About 104,825 shares traded. Endocyte, Inc. (ECYT) has risen 444.08% since June 12, 2017 and is uptrending. It has outperformed by 431.51% the S&P500. Some Historical ECYT News: ; 09/05/2018 – ENDOCYTE:-PHASE 3 VISION TRIAL ON TRACK FOR FIRST PATIENT VISIT; 09/05/2018 – ENDOCYTE INC – ANTICIPATES ITS CASH, CASH EQUIVALENTS AND INVESTMENTS BALANCE AT END OF 2018 TO EXCEED $130 MLN; 14/05/2018 – VHCP Management Ii Buys New 6.2% Position in Endocyte; 07/05/2018 – Endocyte Rises for 9 Days: Longest Streak Since IPO; 15/03/2018 – ENDOCYTE INC – THREE OF CO’S CURRENT DIRECTORS INFORMED CO THAT THEY WOULD NOT STAND FOR RE-ELECTION AT 2018 ANNUAL MEETING; 10/04/2018 – Endocyte at Deutsche Bank Health Care Conference May 8; 09/05/2018 – ENDOCYTE ANNOUNCES THE LANCET ONCOLOGY PUBLICATION OF PHASE 2 DATA FROM INVESTIGATOR-INITIATED PROSTATE CANCER TRIAL OF (177)LU-PSMA-617; 15/03/2018 Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments; 16/05/2018 – Endocyte Announces Presentation of Phase 2 Data from lnvestigator-lnitiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; 09/05/2018 – Endocyte Announces The Lancet Oncology Publication of Phase 2 Data From lnvestigator-lnitiated Prostate Cancer Trial of (177)Lu-PSMA-617

More notable recent Endocyte, Inc. (NASDAQ:ECYT) news were published by: Prnewswire.com which released: “Developing Cancer Treatment Trials Positive Indication for Biotech Market” on June 12, 2018, also Nasdaq.com with their article: “Why Endocyte Stock Jumped Higher Today” published on May 17, 2018, Nasdaq.com published: “Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer” on June 05, 2018. More interesting news about Endocyte, Inc. (NASDAQ:ECYT) were released by: Seekingalpha.com and their article: “Endocyte’s radiotherapeutic 177Lu-PSMA-617 shows positive effect in mid-stage prostate cancer study; shares ahead …” published on May 17, 2018 as well as Seekingalpha.com‘s news article titled: “Endocyte enrolls first patient in phase 3 VISION trial of 177lu-psma-617 in prostate cancer” with publication date: June 05, 2018.

Analysts await Endocyte, Inc. (NASDAQ:ECYT) to report earnings on August, 14. They expect $-0.19 earnings per share, up 32.14% or $0.09 from last year’s $-0.28 per share. After $-0.16 actual earnings per share reported by Endocyte, Inc. for the previous quarter, Wall Street now forecasts 18.75% negative EPS growth.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company has market cap of $992.48 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents. It currently has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Since January 1, 0001, it had 0 insider buys, and 1 sale for $45,677 activity.

Ghost Tree Capital Llc holds 4.05% of its portfolio in Endocyte, Inc. for 2.20 million shares. Ra Capital Management Llc owns 3.88 million shares or 2.7% of their US portfolio. Moreover, Venbio Select Advisor Llc has 2.47% invested in the company for 5.70 million shares. The California-based Partner Fund Management L.P. has invested 0.8% in the stock. Perceptive Advisors Llc, a New York-based fund reported 2.20 million shares.

Analysts await Fluent, Inc. (NASDAQ:FLNT) to report earnings on August, 8. They expect $0.04 earnings per share, up 121.05% or $0.23 from last year’s $-0.19 per share. FLNT’s profit will be $3.01 million for 18.25 P/E if the $0.04 EPS becomes a reality. After $0.03 actual earnings per share reported by Fluent, Inc. for the previous quarter, Wall Street now forecasts 33.33% EPS growth.

Fluent, Inc., a data and analytics company, provides cloud information and performance marketing solutions to enterprises in various industries in the United States. The company has market cap of $220.01 million. It operates in two divisions, Information Services and Performance Marketing. It currently has negative earnings. The Information Services segment provides solutions to organizations in the risk management and consumer marketing industries.

An insider Ryan Schulke who is Chief Executive Officer of Fluent Inc purchased some 500,000 shares of the Pinksheet-listed company having a value near $1.40 million USD calculated based on $2.8 for each one share. Ryan is trying to increase his company’s share, same as he did in the last month. He purchased another 37,000 shares worth $90,650 USD. The dated June 12, 2018 transaction’s Form 4 submitted with the Security Exchange Commission is ready for review here. Currently, Mr. Ryan, possess 2.55 million shares, which accounts for 10%+ of the company’s market cap.

The stock increased 0.86% or $0.02 during the last trading session, reaching $2.92. About 50,601 shares traded. Fluent, Inc. (NASDAQ:FLNT) has declined 44.66% since June 12, 2017 and is downtrending. It has underperformed by 57.23% the S&P500. Some Historical FLNT News: ; 08/05/2018 – FLUENT INC – QTRLY GAAP SHR LOSS FROM CONT OPS $0.08; 26/04/2018 Fluent, Inc. Taps Katherine Rae to Lead People Strategy; 15/05/2018 – Fluent, Inc. Appoints Brian Hogan to Lead Fluent Health; 24/05/2018 – Fluent Named Marketing EDGE’s 2018 Corporate Disruptor; 24/05/2018 – Fluent Named Marketing EDGE’s 2018 Corporate Disruptor

Endocyte, Inc. (NASDAQ:ECYT) Institutional Positions Chart